Etreo Junior Carneiro da Silva Minarini

Etreo Junior Carneiro da Silva Minarini

Auto-generated profile, based on publicly available information

Etreo Junior Carneiro da Silva Minarini

Graduate Program in Public Health, Nursing Department, Universidade Federal do Espírito Santo, Vitória, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in SAGE Open Nursing
Verified
Journal Article
Open access
EMEtreo Junior Carneiro da Silva Minarini
Etreo Junior Carneiro da Silva Minarini
RPRaphael Manhaes Pessanha
Raphael Manhaes Pessanha
SSSara Isabel Pimentel de Carvalho Schuab
Sara Isabel Pimentel de Carvalho Schuab
NDNaira Santos D’aGostini
Naira Santos D’aGostini
VSVictoria Oliveira Santos
Victoria Oliveira Santos
Luís Carlos Lopes-JúniorLuís Carlos Lopes-Júnior
Luís Carlos Lopes-Júnior
Introduction: Cancer imposes substantial physical and psychological burdens that negatively affect patients’ health-related quality of life (HRQoL). Assessing HRQoL prior to chemotherapy initiation is essential for tailoring early supportive care strategies. Objective: To describe the characteristics and identify the factors associated with HRQoL in newly diagnosed cancer patients immediately before initiating outpatient chemotherapy. Method: This cross-sectional study included adults with newly diagnosed stage I–III cancer scheduled to begin outpatient chemotherapy at a Brazilian cancer referral center. Sociodemographic and tumor-related data were obtained using a structured questionnaire. HRQoL was assessed with the EQ-5D-3L instrument. Descriptive and bivariate analyses were performed using Fisher's exact test. Results: Eighty-four patients were included (mean age: 57.68 years); most were female (72.62%), of mixed ethnicity (40.48%), had completed only primary education (48.81%), and were married (51.19%). The average time from diagnosis to treatment initiation was 120 days, and 60.71% reported comorbidities. Breast cancer was the most common diagnosis (57.14%), predominantly at Stage II (57.14%). The mean EQ-5D-3L index score was 77.79. Comorbidities were significantly associated with impaired mobility ( p = .009), and female patients reported significantly more anxiety and depression than males ( p = .005). Inflammatory markers revealed that most patients had low neutrophil-to-lymphocyte ratio (76.54%), low platelet-to-lymphocyte ratio (72.84%), and elevated C-reactive protein (CRP; 84.52%). In the multivariate analysis, the presence of comorbidities remained significantly associated with worse mobility (OR = 5.456; 95% CI [1.205–24.707]; p = .028), and male sex was independently associated with lower levels of anxiety and depression (OR = 0.206; [0.067–0.634]; p = .006). A nonsignificant trend was also observed between higher CRP levels and increased pain (OR = 2.800; [0.824–9.510]; p = .099). Conclusions: Patients with newly diagnosed cancer experience impaired HRQoL even before starting chemotherapy. Comorbidities were associated with worse mobility, and female patients reported higher levels of anxiety and depression. These findings support the need for early multidisciplinary care to mitigate functional and emotional burdens prior to treatment.